289 results on '"Brockstein, Bruce"'
Search Results
52. Association of a Proactive Swallowing Rehabilitation Program With Feeding Tube Placement in Patients Treated for Pharyngeal Cancer
53. Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
54. Outcomes of chemoradiation (CRT) for locoregionally advanced (LRA)squamous cell carcinoma of the head and neck (SCCHN): Outcomes with weekly cisplatin (WC) in an academic community based hospital.
55. Absolute lymphocyte count (ALC) during and after chemoradiation (CRT) for squamous cell carcinoma of the head and neck (SCCHN): Effect of the regimen and potential therapeutic implications.
56. Overcoming suvivorship care planning implementation challenges through decentralization.
57. Physician Attitudes Toward Advance Care Planning Survey
58. Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
59. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
60. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck
61. Clinical response to anti-PD1 immunotherapy in a patient with non-seminomatous germ cell tumor and evaluation of the immune landscape in testicular cancer.
62. Current clinical immunotherapeutic approaches for head and neck cancer
63. Faculty Opinions recommendation of Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
64. Faculty Opinions recommendation of T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
65. Faculty Opinions recommendation of Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.
66. Faculty Opinions recommendation of Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
67. Faculty Opinions recommendation of Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
68. Faculty Opinions recommendation of T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.
69. Perspectives of Health-Care Providers Toward Advance Care Planning in Patients With Advanced Cancer and Congestive Heart Failure
70. Developing and implementing EMR functionality to improve oral chemotherapy outcomes.
71. Variability of physician perspectives toward advance care planning for patients with incurable cancer and congestive heart failure.
72. Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit
73. Grading financial toxicity based upon its impact on health-related quality of life (HRQol).
74. Reply to S. Chakraborty et al
75. Perspectives of Health-Care Providers Toward Advance Care Planning in Patients With Advanced Cancer and Congestive Heart Failure.
76. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
77. Organ Preservation for Advanced Head and Neck Cancer Concomitant Chemoradiation
78. Chemotherapy
79. Outpatient Advance Care Planning for Patients with Metastatic Cancer: A Pilot Quality Improvement Initiative
80. Evaluation of a risk-adapted visit for post-treatment cancer survivors.
81. EMR optimized oral chemotherapy monitoring program: Adherence and ADR outcomes.
82. Radiation-Induced Leiomyosarcoma: Does Antimetabolite Chemotherapy Contribute? A Report of Three Cases
83. Outpatient documentation of advance care planning (ACP).
84. Evaluation of oral chemotherapy prescribing at an outpatient oncology clinic.
85. Faculty of 1000 evaluation for Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group.
86. Faculty of 1000 evaluation for Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial.
87. Faculty of 1000 evaluation for Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review.
88. Faculty of 1000 evaluation for Psychosocial interventions for patients with head and neck cancer.
89. Faculty of 1000 evaluation for Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer.
90. Faculty of 1000 evaluation for Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
91. Faculty of 1000 evaluation for High Dose Rate versus Low Dose Rate Brachytherapy for Oral Cancer - A Meta-Analysis of Clinical Trials.
92. Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
93. Faculty of 1000 evaluation for Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.
94. Faculty Opinions recommendation of Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
95. Faculty Opinions recommendation of Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
96. Faculty Opinions recommendation of Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
97. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
98. Medical informatics: Documenting quality of end-of-life oncologic care.
99. Implementation and evaluation of a tobacco cessation program in an outpatient oncology center.
100. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.